Navigation Links
Cell Therapeutics, Inc. Intends to Offer to Exchange up to $89.2 Million of its Outstanding Convertible Notes in a 'Modified Dutch Auction' Tender Offer
Date:5/11/2009

SEATTLE, May 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (Nasdaq and MTA: CTIC) today announced that that its Board of Directors has authorized a "Modified Dutch Auction" tender offer (the "Exchange Offer") and that it intends to exchange shares of its common stock, no par value ("Common Stock"), and cash for up to approximately an aggregate of $89.2 million principal amount for the following outstanding shares of the Company's convertible notes (the "Notes"):

  • 4% Convertible Senior Subordinated Notes due 2010
  • 5.75% Convertible Senior Notes due 2011
  • 6.75% Convertible Senior Notes due 2010
  • 7.5% Convertible Senior Notes due 2011
  • 9% Convertible Senior Notes due 2012

The Company currently expects to utilize up to $17.8 million in cash currently on hand and/or cash to be received in connection with a private placement of Common Stock and warrants to a single institutional investor for the cash portion of the exchange consideration. The Company anticipates that the consideration for the Exchange Offer will be in the range of $250 to $300 per $1000 per value of the Notes.

The Company is conducting the Exchange Offer in order to reduce the principal amount of its outstanding indebtedness. The Company believes that reducing its outstanding indebtedness is necessary in order for its business to operate in light of its current asset base and revenue prospects. Currently, there is an aggregate of approximately $118.9 million of Notes outstanding. The Exchange Offer is expected to commence in the near future.

This announcement is for informational purposes only and is not an offer to buy, or the solicitation of an offer to sell, any Notes. The Company expects to announce further information on the details of the proposed Exchange Offer in the near fu
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Oxygen Biotherapeutics, Inc. Files Cosmetic Product Ingredient Statement for new Oxycyte-based Cosmetic Gel
2. TorreyPines Therapeutics, Inc. Hires Advisor to Evaluate Strategic Alternatives
3. Former Executive at Genzyme Corp. and Osiris Therapeutics, Inc. to Head Business Advisory Board at Rx for Africa, Inc.
4. Oxygen Biotherapeutics, Inc. Establishes Warfighter Division
5. Cell Therapeutics, Inc. (CTI) President Craig Philips to Present at Invest Northwest
6. Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes
7. Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results
8. Cell Therapeutics, Inc. (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
9. Cell Therapeutics, Inc. (CTI) Oppenheimer & Co. Healthcare Conference Presentation to be Webcast
10. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
11. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase Up to $18 Million of Senior Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... September 03, 2014 UWDress.com, an experienced ... has added a lot of fashionable bridesmaid dresses ... the company has launched a special offer to celebrate ... price, from 20 to 60 percent off. , ... to announce our new fashionable bridesmaid dresses for consumers ...
(Date:9/2/2014)... Recently, BambooIndustry.com, an excellent company in ... strand woven bamboo floors to celebrate the ... its appreciation to the frequent callers, BambooIndustry.com launched a ... addition to strand woven floors, BambooIndustry.com provides many kinds ... floors, click strand woven floors, click lock floors, wide ...
(Date:9/2/2014)... 03, 2014 Recently, Top 10 ... companies and announced that JustHost ( http://www.justhost.com/track/seohosts ) ... webmasters. , “The hosting suppliers we recommend are ... competitors on hosting features, uptime and server speed ... Best SEO Hosting says. “We believe that BlueHost ...
(Date:9/2/2014)... Cloud Medical Doctor Software Corporation (Cloud-MDs) (OTCQB: ... Business Operations solutions and Billing Services for the Healthcare ... for all industries announced today that its CEO Michael ... the CME in Chicago by PRICE Futures Group Mr. ... very proud of the recognition that our CipherLoc Encryption ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- Complications are rare ... reconstruction, a new study indicates. However, the ... associated with a slightly higher risk for certain ... included more than 18,000 breast cancer patients who ... mastectomy with breast reconstruction and were followed for ...
Breaking Medicine News(10 mins):Health News:Elegant Bridesmaid Dresses For 2014, Latest Designs From UWDress.com 2Health News:Cheap Strand Woven Bamboo Floors For Autumn On Sale At BambooIndustry.com 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2
... diagnosis and treatment of breast cancer-related lymphedema by a ... for intensive rehabilitation, according to an article published in ... the scientific journal of the American Physical Therapy Association ... and spokesperson Nicole Stout, PT, MPT, CLT-LANA, compared a ...
... Air pollution may increase the risk of type 2 diabetes ... study suggests. Previous research has shown that air pollution ... and heart attack, but it hasn,t been known whether it ... and high blood pressure (hypertension). In this study, researchers ...
... 6 (HealthDay News) -- Two new studies from the Mayo ... to blame for a surge in liver cancer cases, which ... hepatocellular carcinoma (HCC), or liver cancer, has only a 10 ... in a Mayo news release. The researchers say their findings ...
... HealthDay Reporter , FRIDAY, Jan. 6 (HealthDay News) ... may have a different type of disease than those with ... well for them, new research suggests. "We are beginning ... molecular mechanisms," said Dr. John Fahy, director of the Airway ...
... new UCSF analysis of tobacco industry documents shows that ... additives in cigarettes, including menthol, obscuring actual toxicity levels ... diseases for smokers. Tobacco industry information can,t be ... their work provides evidence that hundreds of additives, including ...
... of the Journal of the American College of ... pediatric computed tomography (CT) scans. Approximately seven to eight ... indications per year in the United States. ... of reducing radiation dose with CT scanning. A substantial ...
Cached Medicine News:Health News:Prospective surveillance model emerges as standard of care for breast cancer treatment 2Health News:Smog Tied to Raised Risk of Chronic Illness in Black Women 2Health News:Researchers Identify Liver Cancer Risk Factors 2Health News:Study Offers Clues to Why Some Don't Benefit From Asthma Drugs 2Health News:Study Offers Clues to Why Some Don't Benefit From Asthma Drugs 3Health News:Tobacco company misrepresented danger from cigarettes 2Health News:Experts offer pointers for optimizing radiation dose in pediatric CT 2
(Date:9/2/2014)... , Spanje, September 2, 2014 ... GARFIELD AF Registry bij het ESC CONGRESS ... bij patiënten met risico op beroerte in ... Gegevens van bijna 12.500 patiënten ingeschreven ... FIELD-Atrial Fibrillation (GARFIELD-AF), een innovatief, onafhankelijk initiatief ...
(Date:9/2/2014)... , September 2, 2014 ... ESC CONGRESS 2014 provide insight into treatment and ... everyday clinical practice --   Data ... Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an ... stroke prevention strategies for atrial fibrillation (AF) patients ...
(Date:9/2/2014)... -- , Registry provides new insights into ... treatment satisfaction [ 1 ] , ...        (Photo: http://photos.prnewswire.com/prnh/20140902/703596 ) ... Barcelona, Spain : Daiichi Sankyo today announced ... Registry in Atrial Fibrillation (PREFER in AF), revealing significant ...
Breaking Medicine Technology:Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 3Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 4Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 5Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 6Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 7Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 9Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 10Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 2One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 3One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 4One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 5One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 6One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 7One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 8
... 2011 Curemark, LLC , a drug research ... diseases, announced today that its compound CM-182 demonstrated positive ... amphetamines. The mouse model screening was performed by the ... indicated that the amphetamine-injected C57BL/6 mice exhibited a dose ...
... Valeant Pharmaceuticals International, Inc. (the "Company" or "Valeant") ... approved an increase of $300 million under its ... Program").  Under the Securities Repurchase Program, Valeant may ... convertible notes, senior notes, common shares and/or other ...
Cached Medicine Technology:Curemark Reports Positive Results for Novel Compound CM-182 in Amphetamine Induced Hyperactivity 2Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program 2Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program 3
Two prong stainless steel tips; with titanium handle/...
Straight shafts with fine Pierse type tips on a 5mm platform; In Titanium...
Smooth colibri tip; In Titanium....
Gently curved 5mm Platform With 12, 0.12mm Teeth; In Titanium....
Medicine Products: